within Pharmacolibrary.Drugs.ATC.N;

model N03AG04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.00011666666666666667,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 15.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N03AG04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Vigabatrin is an antiepileptic drug used as adjunctive therapy in the treatment of refractory complex partial seizures and as monotherapy for infantile spasms (West syndrome). It is an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), increasing GABA levels in the brain. Approved and in use today in several countries, though usually reserved for refractory cases due to the risk of irreversible visual field defects.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers, single or repeated oral doses, both sexes, various studies.</p><h4>References</h4><ol><li><p>Rey, E, et al., &amp; Olive, G (1992). Vigabatrin. Clinical pharmacokinetics. <i>Clinical pharmacokinetics</i> 23(4) 267–278. DOI:<a href=\"https://doi.org/10.2165/00003088-199223040-00003\">10.2165/00003088-199223040-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1395360/\">https://pubmed.ncbi.nlm.nih.gov/1395360</a></p></li><li><p> (2024). Comparison Table: Some oral antiseizure medications. <i>The Medical letter on drugs and therapeutics</i> 66(1708) e133–e140. DOI:<a href=\"https://doi.org/10.58347/tml.2024.1708b\">10.58347/tml.2024.1708b</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39073881/\">https://pubmed.ncbi.nlm.nih.gov/39073881</a></p></li><li><p>Jacob, S, &amp; Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. <i>Drugs in R&amp;D</i> 16(4) 303–316. DOI:<a href=\"https://doi.org/10.1007/s40268-016-0148-6\">10.1007/s40268-016-0148-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27766590/\">https://pubmed.ncbi.nlm.nih.gov/27766590</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N03AG04;
